Supernus Pharmaceuticals, Inc. (LON:0LB2)
 54.95
 +2.16 (4.09%)
  At close: Oct 29, 2025
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $165.45M USD in the quarter ending June 30, 2025, a decrease of -1.71%. This brings the company's revenue in the last twelve months to $665.13M, up 5.55% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm) 
 $665.13M
Revenue Growth 
 +5.55%
P/S Ratio 
 4.86
Revenue / Employee 
 $986.83K
Employees 
 674
Market Cap 
2.36B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% | 
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% | 
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% | 
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% | 
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Supernus Pharmaceuticals News
- 21 days ago - Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
- 5 weeks ago - Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - Nasdaq
- 6 weeks ago - Supernus Pharmaceuticals: Heading In The Right Direction - Seeking Alpha
- 2 months ago - Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewsWire
- 2 months ago - Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock - Benzinga
- 2 months ago - Supernus Pharmaceuticals Stock Scores RS Rating Upgrade - Investor's Business Daily
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Supernus Pharmaceuticals GAAP EPS of $0.40 beats by $0.46, revenue of $165.5M beats by $11.42M - Seeking Alpha